Ainos, INC 10-Q quarterly reports

Ainos, Inc. reported a substantial decrease in revenue and a widening net loss for the second quarter of 2026, primarily due to a strategic shift away from VELDONA pet supplements towards its AI Nose platform, which is still in early commercialization stages.

Ainos reports a net loss of $2.46 million for Q1 2026 while advancing its AI Nose industrial commercialization strategy.

Ainos, Inc. reports increased revenue from its AI Nose platform and VELDONA pet supplements in Q3 2025, but faces continued net losses and significant liquidity challenges.

Ainos, Inc. reported increased net losses for Q2 and H1 2025, but secured a significant $2.1 million AI Nose order with ASE and regained Nasdaq minimum bid price compliance.

Ainos Inc. reports a 412% increase in revenue for Q1 2025, driven by VOC sensing product sales and strategic partnerships, while continuing to invest in AI-driven healthcare and technology.

Ainos Inc. reported a net loss for the third quarter of 2024, while continuing to invest in research and development, particularly in its AI Nose technology and VELDONA drug candidates.

Ainos Inc. reported a widened net loss for the second quarter of 2024, driven by increased operating expenses as the company continues to invest in its product pipeline and clinical trials.

Ainos Inc. reported a net loss of $3.3 million for the first quarter of 2024, with a decrease in revenue as the company pivots away from COVID-19 test kits.

Ainos Inc. reported a significant decrease in revenue for the third quarter of 2023, primarily due to reduced sales of COVID-19 test kits, while the company focuses on new product development and commercialization.